← Back to Analyst Consensus 
SMMT Buy
Summit Therapeutics Inc.
Current Price —
Implied Upside —
Analysts 24
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 2 reiterations from 2 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 1, 2026 | Barclays | maintain | Equal-Weight → Equal-Weight | — | 53% |
| Sep 29, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Sep 23, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | — | 44% |
| Sep 9, 2026 | Jefferies | upgrade | Hold → Buy | — | 52% |
| Aug 26, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | — | 44% |
| Aug 25, 2026 | Bernstein | upgrade | Underperform → Market Perform | — | 52% |
| Aug 18, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | — | 44% |
| Aug 12, 2026 | Leerink Partners | upgrade | Underperform → Market Perform | — | 51% |
| Jul 24, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| Jul 24, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 23, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | — | 44% |
| May 22, 2026 | Bernstein | initiate | — → Underperform | — | 52% |
| May 22, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| May 4, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 1, 2026 | Piper Sandler | maintain | Neutral → Neutral | — | 54% |
| Apr 8, 2026 | Stifel | initiate | Buy → Buy | — | 53% |
| Mar 16, 2026 | Jefferies | downgrade | Buy → Hold | — | 52% |
| Feb 24, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $30 | 44% |
| Feb 2, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Jan 30, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | $40 | 46% |
| Dec 17, 2025 | Barclays | upgrade | Underweight → Equal-Weight | $18 | 53% |
| Nov 18, 2025 | Wolfe Research | initiate | — → Peer Perform | $0 | 53% |
| Oct 22, 2025 | Guggenheim | reiterate | Buy → Buy | $40 | 52% |
| Oct 21, 2025 | Barclays | maintain | Underweight → Underweight | $16 | 53% |
| Oct 21, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $40 | 44% |
| Oct 20, 2025 | Citigroup | maintain | Buy → Buy | $40 | 54% |
| Oct 20, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $40 | 53% |
| Sep 17, 2025 | Barclays | initiate | — → Underweight | $13 | 53% |
| Sep 16, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
| Sep 8, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Sep 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
| Sep 4, 2025 | Guggenheim | initiate | — → Buy | $40 | 52% |
| Sep 3, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $40 | 53% |
| Sep 2, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
| Aug 27, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $50 | 44% |
| Aug 19, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $40 | 53% |
| Aug 19, 2025 | Piper Sandler | initiate | — → Neutral | $21 | 54% |
| Aug 15, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $44 | 44% |
| Aug 12, 2025 | Evercore ISI Group | maintain | Outperform → Outperform | $34 | 58% |
| Jul 1, 2025 | UBS | initiate | — → Buy | $30 | 54% |
| Jul 1, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $44 | 44% |
| Jun 11, 2025 | Leerink Partners | initiate | — → Underperform | $12 | 51% |
| Jun 2, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $40 | 53% |
| May 2, 2025 | Goldman Sachs | maintain | Buy → Buy | $41 | 54% |
| Apr 28, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $40 | 53% |
| Apr 25, 2025 | Jefferies | maintain | Buy → Buy | $44 | 52% |
| Apr 23, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Mar 26, 2025 | Citigroup | upgrade | Neutral → Buy | $35 | 54% |
| Mar 21, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Mar 12, 2025 | Evercore ISI Group | initiate | — → Outperform | $30 | 58% |
Price Target Trend
Aug 13, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days